UY28229A1 - Sal cristalina clorhidrato maleato de s-(2-(1-iminoetil)amino)etil)-2-metil-l.cisteína - Google Patents
Sal cristalina clorhidrato maleato de s-(2-(1-iminoetil)amino)etil)-2-metil-l.cisteínaInfo
- Publication number
- UY28229A1 UY28229A1 UY28229A UY28229A UY28229A1 UY 28229 A1 UY28229 A1 UY 28229A1 UY 28229 A UY28229 A UY 28229A UY 28229 A UY28229 A UY 28229A UY 28229 A1 UY28229 A1 UY 28229A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compound
- amino
- methyl
- salt
- lcisteine
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- -1 AMINO Chemical class 0.000 title abstract 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 title 1
- 229960003750 ethyl chloride Drugs 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 4
- FXNSRODXMVUCNJ-ODZAUARKSA-N (z)-but-2-enedioic acid;hydrochloride Chemical compound Cl.OC(=O)\C=C/C(O)=O FXNSRODXMVUCNJ-ODZAUARKSA-N 0.000 abstract 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/26—Separation; Purification; Stabilisation; Use of additives
- C07C319/28—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Se describe una nueva sal mixta de S-(2-((1-iminoetil)amino)etil-2-metil-L-cisteína (compuesto A). La nueva sal mixta, clorhidrato maleato del (compuesto A), puede producirse para formar cristales que pueden disponerse en forma de aglomerados generalmente empaquetados ordenadamente que son particularmente útiles en la preparación de composiciones farmacéuticas. Se describen también dichas composiciones farmacéuticas, así como procedimientos para preparar clorhidrato maleato de (compuesto A) cristalino, y procedimientos de tratamiento de afecciones caracterizadas por una sobreexpresión de óxido nítrico por la isoforma inducible de la óxido nítrico sintasa utilizando el clorhidrato maleato del (compuesto A ).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45349603P | 2003-03-11 | 2003-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28229A1 true UY28229A1 (es) | 2004-11-08 |
Family
ID=32990778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28229A UY28229A1 (es) | 2003-03-11 | 2004-03-11 | Sal cristalina clorhidrato maleato de s-(2-(1-iminoetil)amino)etil)-2-metil-l.cisteína |
Country Status (33)
Country | Link |
---|---|
US (2) | US20050038120A1 (es) |
EP (1) | EP1603872B1 (es) |
JP (1) | JP4794433B2 (es) |
KR (2) | KR100927911B1 (es) |
CN (1) | CN100460387C (es) |
AR (1) | AR043521A1 (es) |
AT (1) | ATE509909T1 (es) |
AU (1) | AU2004220266B2 (es) |
BR (1) | BRPI0408226A (es) |
CA (1) | CA2518745C (es) |
CL (1) | CL2004000472A1 (es) |
CO (1) | CO5611122A2 (es) |
CY (1) | CY1112461T1 (es) |
DK (1) | DK1603872T3 (es) |
ES (1) | ES2363001T3 (es) |
GT (1) | GT200400040A (es) |
HK (1) | HK1088301A1 (es) |
IL (1) | IL170554A (es) |
MX (1) | MXPA05008674A (es) |
NL (1) | NL1025691C2 (es) |
NO (1) | NO20054645L (es) |
NZ (1) | NZ574218A (es) |
PA (1) | PA8597701A1 (es) |
PE (1) | PE20050309A1 (es) |
PL (1) | PL1603872T3 (es) |
PT (1) | PT1603872E (es) |
RU (1) | RU2357953C2 (es) |
SG (1) | SG155782A1 (es) |
SI (1) | SI1603872T1 (es) |
TW (1) | TWI352076B (es) |
UY (1) | UY28229A1 (es) |
WO (1) | WO2004080956A1 (es) |
ZA (1) | ZA200506459B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6094101A (en) * | 1999-03-17 | 2000-07-25 | Tropian, Inc. | Direct digital frequency synthesis enabling spur elimination |
JP4637178B2 (ja) * | 2004-09-21 | 2011-02-23 | ヴィヴェス,ホアン イグレシアス | 赤外線を用いた粉末材料の造粒及び/又は乾燥方法及び装置 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1070849C (zh) * | 1994-06-15 | 2001-09-12 | 惠尔康基金会集团公司 | 酶抑制剂 |
MY135721A (en) * | 2000-03-24 | 2008-06-30 | Pharmacia Corp | Amidino compounds useful as nitric oxide synthase inhibitors |
AR031609A1 (es) * | 2000-09-15 | 2003-09-24 | Pharmacia Corp | Derivados de acido 2-amino-2-alquil-3 heptenoico y heptinoico utiles como inhibidores de oxido nitrico sintetasa |
AR031608A1 (es) * | 2000-09-15 | 2003-09-24 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
-
2004
- 2004-03-04 KR KR1020057016858A patent/KR100927911B1/ko not_active IP Right Cessation
- 2004-03-04 PT PT04717188T patent/PT1603872E/pt unknown
- 2004-03-04 EP EP04717188A patent/EP1603872B1/en not_active Expired - Lifetime
- 2004-03-04 NZ NZ574218A patent/NZ574218A/en not_active IP Right Cessation
- 2004-03-04 PL PL04717188T patent/PL1603872T3/pl unknown
- 2004-03-04 SI SI200431696T patent/SI1603872T1/sl unknown
- 2004-03-04 WO PCT/IB2004/000678 patent/WO2004080956A1/en active Application Filing
- 2004-03-04 KR KR1020097008258A patent/KR20090048521A/ko not_active Application Discontinuation
- 2004-03-04 BR BRPI0408226-5A patent/BRPI0408226A/pt not_active IP Right Cessation
- 2004-03-04 DK DK04717188.9T patent/DK1603872T3/da active
- 2004-03-04 ES ES04717188T patent/ES2363001T3/es not_active Expired - Lifetime
- 2004-03-04 AT AT04717188T patent/ATE509909T1/de active
- 2004-03-04 CA CA2518745A patent/CA2518745C/en not_active Expired - Fee Related
- 2004-03-04 CN CNB200480012896XA patent/CN100460387C/zh not_active Expired - Fee Related
- 2004-03-04 SG SG200802031-5A patent/SG155782A1/en unknown
- 2004-03-04 AU AU2004220266A patent/AU2004220266B2/en not_active Ceased
- 2004-03-04 RU RU2005125833/04A patent/RU2357953C2/ru not_active IP Right Cessation
- 2004-03-04 JP JP2006506318A patent/JP4794433B2/ja not_active Expired - Fee Related
- 2004-03-04 MX MXPA05008674A patent/MXPA05008674A/es active IP Right Grant
- 2004-03-09 PE PE2004000257A patent/PE20050309A1/es not_active Application Discontinuation
- 2004-03-09 AR ARP040100751A patent/AR043521A1/es not_active Application Discontinuation
- 2004-03-09 CL CL200400472A patent/CL2004000472A1/es unknown
- 2004-03-10 US US10/797,462 patent/US20050038120A1/en not_active Abandoned
- 2004-03-10 TW TW093106315A patent/TWI352076B/zh not_active IP Right Cessation
- 2004-03-10 GT GT200400040A patent/GT200400040A/es unknown
- 2004-03-10 PA PA20048597701A patent/PA8597701A1/es unknown
- 2004-03-11 UY UY28229A patent/UY28229A1/es not_active Application Discontinuation
- 2004-03-11 NL NL1025691A patent/NL1025691C2/nl not_active IP Right Cessation
-
2005
- 2005-08-11 ZA ZA200506459A patent/ZA200506459B/en unknown
- 2005-08-29 IL IL170554A patent/IL170554A/en not_active IP Right Cessation
- 2005-09-09 CO CO05091013A patent/CO5611122A2/es not_active Application Discontinuation
- 2005-10-10 NO NO20054645A patent/NO20054645L/no not_active Application Discontinuation
-
2006
- 2006-08-04 HK HK06108667.9A patent/HK1088301A1/xx not_active IP Right Cessation
-
2008
- 2008-12-05 US US12/315,744 patent/US7767850B2/en not_active Expired - Fee Related
-
2011
- 2011-06-06 CY CY20111100540T patent/CY1112461T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110019A2 (es) | Forma cristalina de un compuesto de quinolinona-carboxamida | |
MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
NO20063517L (no) | Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den | |
EA201890254A3 (ru) | Ингибиторы глюкозилцерамидсинтазы | |
JO2962B1 (en) | Aminopronic derivatives substituted as niprilicin inhibitors | |
RU2011139107A (ru) | Специфические соединения диарилгидантоина и диарилтиогидантоина | |
TW200744586A (en) | Therapeutic compounds | |
NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
BRPI0600796A (pt) | forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo | |
CY1109072T1 (el) | Βητα κρυσταλλικη μορφη του υδροχλωρικου αλατος της ιβαμπραδινης, μεθοδος παρασκευης αυτου και φαρμακευτικης συνθεσεις που το περιεχουν | |
DK1758463T3 (da) | Guanidinoeddikesyre som fodermiddeltilsætning | |
TW200833663A (en) | Therapeutic agents | |
NO20063518L (no) | Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den | |
UY32598A (es) | Sal de abt-263 y formas en estado sólido de la misma | |
BRPI0600795A (pt) | forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo | |
BR0312975A (pt) | Forma cristalina de agonista de receptor adrenérgico ß2 | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
TW200639159A (en) | Treatment of pain | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
MX2007007025A (es) | Nuevos derivados de hidantoina como inhibidores de metaloproteinasa. | |
BRPI0920605A8 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste. | |
DE60306546D1 (de) | Entzündungshemmende 3-arylthio-3-thiazolylalkylamine | |
ECSP099602A (es) | Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas | |
MX2020005564A (es) | Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas. | |
MX2023000521A (es) | Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150514 |